Published in Lancet on May 24, 1997
Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med (2008) 6.17
Reprogramming of the macrophage transcriptome in response to interferon-gamma and Mycobacterium tuberculosis: signaling roles of nitric oxide synthase-2 and phagocyte oxidase. J Exp Med (2001) 3.75
Mycobacterium tuberculosis exploits human interferon γ to stimulate macrophage extracellular trap formation and necrosis. J Infect Dis (2013) 2.27
Cytokines in innate host defense in the lung. J Clin Invest (2002) 1.66
Attenuated host resistance against Mycobacterium bovis BCG infection in mice lacking osteopontin. Infect Immun (1999) 1.65
Macrophage apoptosis in tuberculosis. Yonsei Med J (2009) 1.62
Correlates of protective immunity to Mycobacterium tuberculosis in humans. Clin Infect Dis (2000) 1.46
Modeling the immune rheostat of macrophages in the lung in response to infection. Proc Natl Acad Sci U S A (2009) 1.38
CpG oligodeoxynucleotides enhance host defense during murine tuberculosis. Infect Immun (2002) 1.16
Dichotomy of cytokine profiles in patients and high-risk healthy subjects exposed to tuberculosis. Infect Immun (1999) 1.15
Resident Th1-like effector memory cells in pulmonary recall responses to Mycobacterium tuberculosis. Am J Respir Cell Mol Biol (2005) 1.13
Recombinant gamma interferon stimulates signal transduction and gene expression in alveolar macrophages in vitro and in tuberculosis patients. Infect Immun (2003) 1.07
Exogenous gamma and alpha/beta interferon rescues human macrophages from cell death induced by Bacillus anthracis. Infect Immun (2004) 1.07
Efficacy of Mycobacterium indicus pranii immunotherapy as an adjunct to chemotherapy for tuberculosis and underlying immune responses in the lung. PLoS One (2012) 1.05
Rising to the challenge: new therapies for tuberculosis. Trends Microbiol (2013) 1.04
Influence of disease severity on nitrite and cytokine production by peripheral blood mononuclear cells (PBMC) from patients with pulmonary tuberculosis (TB). Clin Exp Immunol (2000) 1.02
T cell-mediated host immune defenses in the lung. Annu Rev Immunol (2013) 1.00
Genetics and pulmonary medicine. 5. Genetics of drug resistant tuberculosis. Thorax (1998) 0.99
Differential expression of gamma interferon mRNA induced by attenuated and virulent Mycobacterium tuberculosis in guinea pig cells after Mycobacterium bovis BCG vaccination. Infect Immun (2003) 0.98
Host-directed therapeutics for tuberculosis: can we harness the host? Microbiol Mol Biol Rev (2013) 0.97
Low in vitro production of interferon-gamma and tumor necrosis factor-alpha in HIV-seronegative patients with pulmonary disease caused by nontuberculous mycobacteria. J Clin Immunol (2000) 0.95
Immunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosis. PLoS One (2009) 0.95
Cytokine and lipid mediator networks in tuberculosis. Immunol Rev (2015) 0.94
Aerosolized gamma interferon (IFN-gamma) induces expression of the genes encoding the IFN-gamma-inducible 10-kilodalton protein but not inducible nitric oxide synthase in the lung during tuberculosis. Infect Immun (2004) 0.93
Compartmentalized bronchoalveolar IFN-gamma and IL-12 response in human pulmonary tuberculosis. Tuberculosis (Edinb) (2008) 0.92
Alcoholic lung injury: metabolic, biochemical and immunological aspects. Toxicol Lett (2013) 0.91
Adjuvant interferon gamma in patients with drug - resistant pulmonary tuberculosis: a pilot study. BMC Infect Dis (2004) 0.89
Intranasal IFNgamma extends passive IgA antibody protection of mice against Mycobacterium tuberculosis lung infection. Clin Exp Immunol (2006) 0.89
Inhaled therapeutics for prevention and treatment of pneumonia. Expert Opin Drug Saf (2009) 0.89
Determinants of natural immunity against tuberculosis in an endemic setting: factors operating at the level of macrophage-Mycobacterium tuberculosis interaction. Clin Exp Immunol (2008) 0.87
Recent advances in our understanding of human host responses to tuberculosis. Respir Res (2001) 0.86
Six-month therapy with aerosolized interferon-gamma for refractory multidrug-resistant pulmonary tuberculosis. J Korean Med Sci (2004) 0.85
Application of nanotechnologies for improved immune response against infectious diseases in the developing world. Adv Drug Deliv Rev (2009) 0.84
Gamma interferon and monophosphoryl lipid A-trehalose dicorynomycolate are efficient adjuvants for Mycobacterium tuberculosis multivalent acellular vaccine. Infect Immun (2005) 0.83
IFN-gamma impairs release of IL-8 by IL-1beta-stimulated A549 lung carcinoma cells. BMC Cancer (2008) 0.83
CD4 T Cell-Derived IFN-γ Plays a Minimal Role in Control of Pulmonary Mycobacterium tuberculosis Infection and Must Be Actively Repressed by PD-1 to Prevent Lethal Disease. PLoS Pathog (2016) 0.83
Immunotherapeutic effects of recombinant adenovirus encoding granulocyte-macrophage colony-stimulating factor in experimental pulmonary tuberculosis. Clin Exp Immunol (2013) 0.82
Cell-autonomous effector mechanisms against mycobacterium tuberculosis. Cold Spring Harb Perspect Med (2014) 0.82
Extracellular traps and macrophages: new roles for the versatile phagocyte. J Leukoc Biol (2015) 0.81
Adjuvant interferon gamma in patients with pulmonary atypical Mycobacteriosis: a randomized, double-blind, placebo-controlled study. BMC Infect Dis (2008) 0.81
Exogenous interferon-alpha and interferon-gamma increase lethality of murine inhalational anthrax. PLoS One (2007) 0.81
Aerosolized gentamicin reduces the burden of tuberculosis in a murine model. Antimicrob Agents Chemother (2011) 0.79
Defective monocyte oxidative burst predicts infection in alcoholic hepatitis and is associated with reduced expression of NADPH oxidase. Gut (2016) 0.79
New drugs and regimens for treatment of TB. Expert Rev Anti Infect Ther (2010) 0.77
Adenosine deaminase acting on RNA-1 (ADAR1) inhibits HIV-1 replication in human alveolar macrophages. PLoS One (2014) 0.76
Host-Directed Therapies for Tuberculosis. Cold Spring Harb Perspect Med (2015) 0.76
Biodefense shield and avian influenza. Emerg Infect Dis (2006) 0.75
Interferon-gamma for respiratory diseases. Lancet (1997) 0.75
Immune modulation in the treatment of respiratory infection. Respir Res (2000) 0.75
Immunotherapy for tuberculosis: future prospects. Immunotargets Ther (2016) 0.75
Role of Interferons in the Development of Diagnostics, Vaccines, and Therapy for Tuberculosis. J Immunol Res (2017) 0.75
Increased incidence of multidrug-resistant tuberculosis in diabetic patients on the Bellevue Chest Service, 1987 to 1997. Chest (2001) 3.10
Amplification of DNA of Mycobacterium tuberculosis from peripheral blood of patients with pulmonary tuberculosis. Lancet (1994) 3.04
Exaggerated spontaneous release of platelet-derived growth factor by alveolar macrophages from patients with idiopathic pulmonary fibrosis. N Engl J Med (1987) 2.62
Mechanisms of stimulation of interleukin-1 beta and tumor necrosis factor-alpha by Mycobacterium tuberculosis components. J Clin Invest (1993) 2.38
The host immune response to tuberculosis. Am J Respir Crit Care Med (1998) 2.35
Severe measles pneumonitis in adults: evaluation of clinical characteristics and therapy with intravenous ribavirin. Clin Infect Dis (1994) 2.30
Enhanced IL-1 beta and tumor necrosis factor-alpha release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure. J Immunol (1993) 2.04
What is the role of nitric oxide in murine and human host defense against tuberculosis?Current knowledge. Am J Respir Cell Mol Biol (2001) 1.98
Outcome of MDR-TB patients, 1983-1993. Prolonged survival with appropriate therapy. Am J Respir Crit Care Med (1996) 1.88
Enhanced interleukin-8 release and gene expression in macrophages after exposure to Mycobacterium tuberculosis and its components. J Clin Invest (1995) 1.85
Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication in the lung. Am J Respir Crit Care Med (1997) 1.83
Time to detection of Mycobacterium tuberculosis in sputum culture correlates with outcome in patients receiving treatment for pulmonary tuberculosis. Chest (1998) 1.79
Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. Am J Med Genet (1998) 1.75
Detection of K-ras oncogene mutations in bronchoalveolar lavage fluid for lung cancer diagnosis. J Natl Cancer Inst (1995) 1.70
Hemoptysis: prospective high-resolution CT/bronchoscopic correlation. Chest (1994) 1.68
Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication by transcriptional activation at the long terminal repeat. J Clin Invest (1995) 1.68
Effect of Mycobacterium tuberculosis and its components on macrophages and the release of matrix metalloproteinases. Thorax (1996) 1.61
Increased release of interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha by bronchoalveolar cells lavaged from involved sites in pulmonary tuberculosis. Am J Respir Crit Care Med (1996) 1.60
Activation of the interleukin 6 gene by Mycobacterium tuberculosis or lipopolysaccharide is mediated by nuclear factors NF-IL6 and NF-kappa B. Proc Natl Acad Sci U S A (1994) 1.50
Screening by specialists to reduce unnecessary test ordering in patients evaluated for tuberculosis. Chest (1998) 1.45
Local immune responses correlate with presentation and outcome in tuberculosis. Am J Respir Crit Care Med (1998) 1.44
Effects of mycobacteria on regulation of apoptosis in mononuclear phagocytes. Infect Immun (1997) 1.44
Pleural tuberculosis and HIV infection. Chest (1994) 1.42
Risk factors for rifampin-monoresistant tuberculosis: A case-control study. Am J Respir Crit Care Med (1999) 1.33
Comprehensive tuberculosis control for patients at high risk for noncompliance. Am J Respir Crit Care Med (1995) 1.31
Tuberculosis in HIV-positive patients: cellular response and immune activation in the lung. Am J Respir Crit Care Med (1996) 1.29
Regulation of the interleukin-1 beta (IL-1 beta) gene by mycobacterial components and lipopolysaccharide is mediated by two nuclear factor-IL6 motifs. Mol Cell Biol (1993) 1.28
Peripheral-blood-based PCR assay to identify patients with active pulmonary tuberculosis. Lancet (1996) 1.27
Isolation of the gene for the beta subunit of RNA polymerase from rifampicin-resistant Mycobacterium tuberculosis and identification of new mutations. Am J Respir Cell Mol Biol (1994) 1.20
Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma. Cancer Res (1995) 1.20
Current approaches to the diagnosis of active pulmonary tuberculosis. Am J Respir Crit Care Med (1994) 1.18
Pneumoconiosis and exposures of dental laboratory technicians. Am J Public Health (1984) 1.18
The effects of increasing incentives on adherence to tuberculosis directly observed therapy. Int J Tuberc Lung Dis (2000) 1.17
The significance of Mycobacterium avium complex cultivation in the sputum of patients with pulmonary tuberculosis. Chest (1997) 1.16
Hut lung. A domestically acquired particulate lung disease. Medicine (Baltimore) (2000) 1.13
Cytokine gene activation and modified responsiveness to interleukin-2 in the blood of tuberculosis patients. J Infect Dis (1993) 1.12
Enhanced insulin-like growth factor molecules in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (1995) 1.12
Early responses to infection: chemokines as mediators of inflammation. Curr Opin Immunol (1997) 1.11
Effects of lead on the female and reproduction: a review. Mt Sinai J Med (1977) 1.10
Early inhibition of mycobacterial growth by human alveolar macrophages is not due to nitric oxide. Am J Respir Crit Care Med (1998) 1.10
Clinical utility of the polymerase chain reaction in the diagnosis of infections due to Mycobacterium tuberculosis. Chest (1994) 1.09
Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved--deletion of the viral E1b-19-kD gene increases the viral oncolytic effect. Hum Gene Ther (2001) 1.08
Molecular regulation of IL-6 activation by asbestos in lung epithelial cells: role of reactive oxygen species. J Immunol (1997) 1.06
Biomarkers of lung inflammation in recreational joggers exposed to ozone. Am J Respir Crit Care Med (1996) 1.05
Respiratory disease in Utah coal miners. Am Rev Respir Dis (1981) 1.05
Mycobacterium tuberculosis alters expression of adhesion molecules on monocytic cells. Infect Immun (1994) 1.05
Transbronchial needle aspiration (TBNA) in patients infected with HIV. Am J Respir Crit Care Med (1998) 1.04
Basophilic stippling of red blood cells: a nonspecific finding of multiple etiology. Am J Ind Med (1984) 1.04
The polymerase chain reaction in the diagnosis and evaluation of pulmonary infections. Am J Respir Crit Care Med (1995) 1.03
Morphologic characterization of alveolar macrophages from subjects with occupational exposure to inorganic particles. Am Rev Respir Dis (1989) 1.02
The third epidemic--multidrug-resistant tuberculosis. Chest (1994) 1.02
Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expression. Gene Ther (2005) 1.01
Normal human mesothelial cells and mesothelioma cell lines express insulin-like growth factor I and associated molecules. Cancer Res (1993) 1.01
Tuberculosis following solid organ transplantation. Transpl Infect Dis (2009) 0.99
Increasing incidence of Mycobacterium xenopi at Bellevue hospital: An emerging pathogen or a product of improved laboratory methods? Chest (2000) 0.99
Health effects among refrigeration repair workers exposed to fluorocarbons. Br J Ind Med (1986) 0.98
Asbestos-induced sister chromatid exchanges in cultured Chinese hamster ovarian fibroblast cells. J Environ Pathol Toxicol (1980) 0.97
Acute tropical pulmonary eosinophilia. Characterization of the lower respiratory tract inflammation and its response to therapy. J Clin Invest (1987) 0.97
Activation of NF-kappaB in Mycobacterium tuberculosis- induced interleukin-2 receptor expression in mononuclear phagocytes. Am J Respir Crit Care Med (1999) 0.95
A simple technique for fat biopsy of PBB-exposed individuals. Environ Health Perspect (1978) 0.95
Deletion of the adenoviral E1b-19kD gene enhances tumor cell killing of a replicating adenoviral vector. Hum Gene Ther (2000) 0.93
The value of end-of-treatment chest radiograph in predicting pulmonary tuberculosis relapse. Int J Tuberc Lung Dis (2008) 0.93
In situ activation of helper T cells in the lung. Infect Immun (2001) 0.93
Review: pneumothorax in patients with AIDS-related Pneumocystis carinii pneumonia. Am J Med Sci (1996) 0.92
Mycobacterium tuberculosis induces CCL18 expression in human macrophages. Scand J Immunol (2008) 0.91
The use of asbestos-cement pipe for public water supply and the incidence of cancer in selected communities in Utah. J Community Health (1984) 0.91
Chronic lung disease secondary to ammonia inhalation injury: a report on three cases. Am J Ind Med (1996) 0.91
Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: the importance of the adenoviral E1b-55kD gene. Hum Gene Ther (1999) 0.90
Inhibition of anchorage-independent growth and lung metastasis of A549 lung carcinoma cells by IkappaBbeta. Oncogene (2001) 0.90
Transforming growth factor-beta (TGF-beta) in silicosis. Am J Respir Crit Care Med (1996) 0.90
Relationship between lung cancer and distance of residence from nonferrous smelter stack effluent. Am J Ind Med (1981) 0.90
Modification of the p53 transgene of a replication-competent adenovirus prevents mdm2- and E1b-55kD-mediated degradation of p53. Cancer Gene Ther (2006) 0.90
Spinal tuberculosis in patients with human immunodeficiency virus infection: clinical presentation, therapy and outcome. Tuber Lung Dis (1996) 0.88
Toxicity by interaction of tricyclic antidepressant and monoamine oxidase inhibitor. Calif Med (1972) 0.88
Longitudinal evaluation of pulmonary function in copper smelter workers exposed to sulfur dioxide. Am Rev Respir Dis (1986) 0.86
Trends in mortality of diffuse malignant mesothelioma of pleura. Lancet (1983) 0.86
Reversible beryllium sensitization in a prospective study of beryllium workers. Arch Environ Health (1984) 0.86
Pulmonary aspergilloma and AIDS. A comparison of HIV-infected and HIV-negative individuals. Chest (1997) 0.85
Screening for infection and disease as a tuberculosis control measure among indigents in New York City, 1994-1997. Int J Tuberc Lung Dis (1999) 0.85
Endemic tuberculosis among homeless men in New York City. Arch Intern Med (1994) 0.85
Immunohistochemical localization of transforming growth factor beta isoforms in asbestos-related diseases. Environ Health Perspect (1997) 0.84
Health implications of natural fibrous zeolites for the Intermountain West. Environ Res (1983) 0.84
Intrathoracic adenopathy associated with pulmonary tuberculosis in patients with human immunodeficiency virus infection. Chest (1993) 0.84
Preventing the next generation of extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis (2010) 0.84
Differentiation of the ILO boundary chest roentgenograph (0/1 to 1/0) in asbestosis by high-resolution computed tomography scan, alveolitis, and respiratory impairment. J Occup Environ Med (1996) 0.84
Lipophosphoglycan from Leishmania suppresses agonist-induced interleukin 1 beta gene expression in human monocytes via a unique promoter sequence. Proc Natl Acad Sci U S A (1996) 0.84
Elevated IP-10 and IL-6 from bronchoalveolar lavage cells are biomarkers of non-cavitary tuberculosis. Int J Tuberc Lung Dis (2013) 0.84
Sister chromatid exchange frequency in asbestos workers. J Natl Cancer Inst (1983) 0.83
Correction of glycogen storage disease type II by enzyme replacement with a recombinant human acid maltase produced by over-expression in a CHO-DHFR(neg) cell line. Biochem Biophys Res Commun (2000) 0.83
The gene for lysosomal protein CD63 is normal in patients with Hermansky-Pudlak syndrome. Lung (1998) 0.83
Transmission trends for human immunodeficiency virus associated tuberculosis in New York City. Int J Tuberc Lung Dis (2005) 0.83
Prevalence of workplace exacerbation of asthma symptoms in an urban working population of asthmatics. J Occup Environ Med (2006) 0.82